UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000023298
Receipt No. R000026742
Scientific Title Evaluation of the treatment efficacy by incrementally increasing dosage of cow's milk on patients with lactose intolerance
Date of disclosure of the study information 2016/07/22
Last modified on 2019/01/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of the treatment efficacy by incrementally increasing dosage of cow's milk on patients with lactose intolerance
Acronym The lactose intolerance treatment by incrementally increasing dosage of cow's milk
Scientific Title Evaluation of the treatment efficacy by incrementally increasing dosage of cow's milk on patients with lactose intolerance
Scientific Title:Acronym The lactose intolerance treatment by incrementally increasing dosage of cow's milk
Region
Japan

Condition
Condition Lactose Intolerance
Classification by specialty
Gastroenterology Pediatrics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Patients who complain of abdominal symptoms due to cow's milk consumption are screened to make sure that there are no clinical symptoms induced by consumption of cow's milk with reduced lactose (excluding psychogenic causes), followed by starting small dosage of general cow's milk with lactose of which amount is incrementally increased (incremental increase of lactose load) on daily basis in order to investigate the improved lactose absorption capacity and the reduced clinical symptoms (acquirement of lactose tolerance). Moreover, changes in intestinal bacterial flora, as well as its roles, are evaluated among before and after the treatment.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Changes in severity of abdominal symptoms before and after the treatment (8 weeks maximum) by continuing incremental increase of cow's milk load for certain period.
Key secondary outcomes 1.Ratio of abdominal symptoms (such as psychogenic causes) in single blind comparative study on cow's milk and lactose-reduced milk
2.Ratio of true lactose intolerance from the result of lactose tolerance test
3.Changes in before and after the treatment listed below
Lactose tolerance test and intestinal bacterial flora

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 After screening by questionnaire survey and agreement to informed consent for the patients with abdominal symptoms due to diary consumption, a single blind comparative study is conducted by observing the abdominal symptoms after dosage of 200ml of lactose-reduced milk and general cow's milk with an interval of 1 week or longer.
Eligible patients with abdominal symptoms only due to cow's milk from the above study have lactose tolerance test and be taken their stool samples prior to the following treatment for lactose tolerance acquirement.
Treatment for lactose tolerance acquirement
The treatment on eligible patients with cow's milk (lactose) intolerance from definitive diagnosis starts with small dosage (30ml) of cow's milk around the same time each day on an empty stomach. If there was no abdominal symptom, the dosage is increased by 30ml with 4 days interval. If the symptoms presented, the same amount is kept for up to 7 days. The study continues up to 8 weeks until the dosage increases to 200ml or more. The daily record of the symptoms is given by each patient during the treatment period.
At the end of the treatment for lactose tolerance acquirement, lactose tolerance test is performed and stool samples are taken on the subjects.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
10 years-old <=
Age-upper limit
70 years-old >
Gender Male and Female
Key inclusion criteria 1.Out-patients in the department of pediatrics, Tokyo Wemens Medical University, Medical Center East and study subjects recruited from collaborative institutes
2.Patients with abdominal symptoms due to cow's milk consumption
Key exclusion criteria 1.Patients with cow's milk allergy
2.Patients with Chronic digestive diseases, hematologic diseases, endocrine/metabolic diseases, and psycho-neurologic diseases
3.Pregnant or expected female patients
4.Other patients that the research director considers to be unsuitable in the study.
Target sample size 40

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Shigetaka Sugihara
Organization Tokyo Women's Medical University,Medical Center East
Division name the department of pediatrics
Zip code
Address 2-1-10 Nishiogu, arakawa-ku, Tokyo
TEL 03-3810-1111
Email sghrsgpd@dnh.twmu.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Kazuko Okada Matsuri Hasegawa
Organization Tokyo Women's Medical University, Medical Center East
Division name the department of pediatrics
Zip code
Address 2-1-10 Nishiogu, arakawa-ku, Tokyo
TEL 03-3810-1111
Homepage URL
Email k.okada-med@nifty.com

Sponsor
Institute Tokyo Women's Medical University Medical Center East
Institute
Department

Funding Source
Organization Japan Dairy Association (J-milk)
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor Jumonji University
Nihon University
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 東京女子医科大学東医療センター Tokyo Wemens Medical University, Medical Center East
小児科(東京都)Department of Pediatrics (Tokyo)

Other administrative information
Date of disclosure of the study information
2016 Year 07 Month 22 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2016 Year 06 Month 01 Day
Date of IRB
Anticipated trial start date
2016 Year 07 Month 22 Day
Last follow-up date
2020 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 07 Month 22 Day
Last modified on
2019 Year 01 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026742

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.